Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | PDE8A | O60658 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE9A | O76083 | 1/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.41 |
| ▸ | PDE6A | P16499 | 1/20 | 0.41 |
| ▸ | PDE6G | P18545 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE6B | P35913 | 1/20 | 0.41 |
| ▸ | PDE6C | P51160 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20893090 | 0.79 | KDR (0.37) | PDE3BPDE3ACHEK1MAP4K4CSF1R | |
| SCHEMBL11880273 | 0.75 | PDE7A (0.42) | ALDH1A1RXFP1PARP1PDE2APDE6D | |
| SCHEMBL20893215 | 0.75 | PSMB8 (0.42) | ALDH1A1RXFP1POLBKDM4EDAO | |
| SCHEMBL12638629 | 0.75 | PARP1 (0.41) | PARP1PDE2APDE6DPDE8APDE5A | |
| SCHEMBL6713740 | 0.75 | ALDH1A1 (0.45) | ALDH1A1PARP1PDE2APDE6DPDE8A | |
| SCHEMBL2818529 | 0.75 | PDE2A (0.69) | ALDH1A1RXFP1PARP1PDE2APDE6D | |
| SCHEMBL30273078 | 0.75 | PDE2A (0.69) | ALDH1A1RXFP1PARP1PDE2APDE6D | |
| SCHEMBL31731798 | 0.73 | MAPK8 (0.40) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31731811 | 0.73 | MAPK8 (0.40) | ALDH1A1PARP1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL5351084 | 0.73 | PARP1 (0.50) | ALDH1A1RXFP1PARP1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3899034-B1 | METHODS FOR RNA ANALYSIS | CureVac SE (DE) | 2026-03-18 | — | — | EP | claimed |
| US-20230201206-A1 | METHODS FOR KILLING ANTIBIOTIC TOLERANT BACTERIA | THE PENN STATE RESEARCH FOUNDATION | 2023-06-29 | — | — | US | claimed |
| EP-3899034-A1 | METHODS FOR RNA ANALYSIS | CureVac AG (DE) | 2021-10-27 | — | — | EP | claimed |
| WO-2020127959-A1 | METHODS FOR RNA ANALYSIS | CUREVAC AG (DE) | 2020-06-25 | — | — | WO | claimed |
| EP-0607076-A1 | 9H-Imidazo 1,2-a benzimidazole derivatives with GABA activity | SYNTHELABO (FR) | 1994-07-20 | — | — | EP | claimed |
| JP-6271575-A | — | — | None | — | — | JP | disclosed |
| EP-3899034-B1 | METHODS FOR RNA ANALYSIS | CureVac SE (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-12538704-B2 | 4H-imidazo[1,2-a]imidazoles for electronic applications | UDC IRELAND LIMITED (IE) | 2026-01-27 | — | — | US | disclosed |
| US-12492425-B2 | Methods for RNA analysis | CureVac SE (DE) | 2025-12-09 | — | — | US | disclosed |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-5639756-A | ANTIDIABETIC AGENTS | ADIR ET COMPAGNIE (FR) | 1997-06-17 | — | — | US | disclosed |
| US-5623073-A | ANTIDIABETIC AGENT | ADIR ET COMPAGNIE (FR) | 1997-04-22 | — | — | US | disclosed |
| WO-1996021662-A1 | THE USE OF HETEROCYCLIC COMPOUNDS AS ANTIOXIDANTS, RADICAL SCAVENGERS, Fe2+ COMPLEXING AGENTS, TISSUE- AND/OR NEUROPROTECTANTS | RISE FRODE (NO) | 1996-07-18 | — | — | WO | disclosed |
| US-5466706-A | Compounds for hypnotics, anxiety or anticonvulsants | SYNTHELABO (FR) | 1995-11-14 | — | — | US | disclosed |
| JP-H06271575-A | 9H-IMIDAZO(1,2-A)BENZIMIDAZOLE-3-ACETOAMIDE DERIVATIVE, ITS PREPARATION AND ITS APPLICATION TO THERAPY | SYNTHELABO SA | 1994-09-27 | — | — | JP | disclosed |
| EP-0607076-A1 | 9H-Imidazo 1,2-a benzimidazole derivatives with GABA activity | SYNTHELABO (FR) | 1994-07-20 | — | — | EP | disclosed |
| US-5149700-A | Antiarrhythmic agent | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
| WO-1991018904-A1 | SUBSTITUTED ARYLSULFONAMIDES AND BENZAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12538704-B2 | 4H-imidazo[1,2-a]imidazoles for electronic applications | RIF1, NR2E1, NR3C1 | ALDH1A1 680/4885RXFP1 678/4885PARP1 602/4885 |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | ALDH1A1 4128/4885RXFP1 4238/4885PARP1 2805/4885 |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | ALDH1A1 4445/4885RXFP1 4840/4885PARP1 1995/4885 |
| US-20230201206-A1 | METHODS FOR KILLING ANTIBIOTIC TOLERANT BACTERIA | CLPP, SPOUT1, CASP3 | ALDH1A1 942/4885RXFP1 4086/4885PARP1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.